• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Moderna (MRNA) Is Up 151.8% After First Positive Phase 3 mRNA Cancer Therapy Result - What's Changed

    Simply Wall St·08/25/2026 23:28:16
    Listen to the news
    • In August 2026, Merck & Co. and Moderna reported positive Phase 3 results from the INTerpath-001 trial, showing that individualized mRNA neoantigen therapy intismeran (V940/mRNA-4157) plus KEYTRUDA improved recurrence-free and distant metastasis-free survival versus KEYTRUDA alone in resected stage IIB–IV melanoma, with no new safety signals.
    • This is the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer therapy, highlighting a potential inflection point for Moderna’s oncology platform beyond its infectious disease vaccines.
    • We’ll now explore how this first positive Phase 3 mRNA cancer therapy result may reshape Moderna’s investment narrative and long-term positioning.

    Find 49 companies with promising cash flow potential yet trading below their fair value.

    Moderna Investment Narrative Recap

    To own Moderna, you need to believe its mRNA platform can expand beyond a shrinking and seasonal COVID and respiratory vaccine base into durable, non-seasonal products like oncology. The INTerpath-001 Phase 3 success strengthens the case that cancer could become a meaningful second pillar, but in the near term the key catalyst remains execution on respiratory launches, while the biggest risk is that revenue volatility and sustained losses persist if new products fail to scale.

    Among recent updates, Moderna’s reaffirmed 2026 revenue guidance and expectation of up to 10% growth stand out in light of the melanoma data. Taken together with the FDA advisory committee’s unanimous backing of mFlusiva for older adults, the company is presenting a picture of steady near term vaccine execution even as the oncology readout introduces a new, longer term source of potential diversification.

    Yet against this optimism, investors should be aware that...

    Read the full narrative on Moderna (it's free!)

    Moderna's narrative projects $3.7 billion revenue and $695.7 million earnings by 2029.

    Uncover how Moderna's forecasts yield a $44.25 fair value, a 72% downside to its current price.

    Exploring Other Perspectives

    MRNA 1-Year Stock Price Chart
    MRNA 1-Year Stock Price Chart

    Against the excitement around melanoma, it is worth remembering the lowest analysts were assuming only about US$2.5 billion of revenue by 2029 and ongoing losses, so their far more pessimistic view on pricing pressure and mRNA demand could shift meaningfully as they reassess this trial result alongside the potential broadening of Moderna’s mRNA platform into personalized cancer vaccines.

    Explore 7 other fair value estimates on Moderna - why the stock might be worth as much as 7% more than the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Moderna research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
    • Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

    Ready To Venture Into Other Investment Styles?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.